GlassScriptPhysician profile
Charles D Swerdlow
NPI 1497727309
$562,297.76
in general payments reported to CMS, 2019-2025
13 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $75K · 2021: $71K · 2022: $77K · 2023: $88K · 2024: $70K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $150K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $12K · Food and Beverage: $5,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $150,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,563.00 |
| Travel and Lodging | $12,301.76 |
| Food and Beverage | $5,518.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $371,439.77 | 2021-2025 | Cobalt Dr Mri Surescan, Evera Mri Xt Dr Surescan, Aurora Ev-Icd Mri Surescan |
| Medtronic Vascular, INC. | $178,286.96 | 2019-2020 | |
| Abbott Laboratories | $3,126.01 | 2019-2024 | Aveir, Tacticath Ablation Catheter, Sensor Enabled, Ensite |
| Boston Scientific Corporation | $2,928.62 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,205.80 | 2019 | |
| Philips North America LLC | $1,950.00 | 2022 | |
| Altathera Pharmaceuticals LLC | $971.99 | 2022-2024 | Sotalol Hydrochloride |
| Medical Device Business Services, INC. | $898.34 | 2019 | |
| Biotronik INC. | $275.33 | 2020-2023 | |
| Biosense Webster, INC. | $92.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.89 | 2022-2023 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $30.95 | 2025 | |
| Amgen INC. | $28.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Swerdlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.